Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa
Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster
Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster
View: Text | PDF
Research Article AIDS/HIV Immunology

Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa

  • Text
  • PDF
Abstract

HIV vaginal transmission accounts for the majority of newly acquired heterosexual infections. However, the mechanism by which HIV spreads from the initial site of viral entry at the mucosal surface of the female genital tract to establish a systemic infection of lymphoid and peripheral tissues is not known. Once the virus exits the mucosa it rapidly spreads to all tissues, leading to CD4+ T cell depletion and the establishment of a viral reservoir that cannot be eliminated with current treatments. Understanding the molecular and cellular requirements for viral dissemination from the genital tract is therefore of great importance, as it could reveal new strategies to lengthen the window of opportunity to target the virus at its entry site in the mucosa where it is the most vulnerable and thus prevent systemic infection. Using HIV vaginal infection of humanized mice as a model of heterosexual transmission, we demonstrate that blocking the ability of leukocytes to respond to chemoattractants prevented HIV from leaving the female genital tract. Furthermore, blocking lymphocyte egress from lymph nodes prevented viremia and infection of the gut. Leukocyte trafficking therefore plays a major role in viral dissemination, and targeting the chemoattractant molecules involved can prevent the establishment of a systemic infection.

Authors

Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster

×

Figure 4

Pertussis toxin (PTX) treatment delays HIV dissemination from the CVT.

Options: View larger image (or click on image) Download as PowerPoint
Pertussis toxin (PTX) treatment delays HIV dissemination from the CVT.
(...
(A) Scheme of the experimental procedure. Daily intravaginal (IVAG) treatment with PBS, pertussis toxin oligomer B (PTB), or PTX was started 3 hours after IVAG HIV. (B) Presence of HIV RNA in plasma at 14 and 21 days postinfection (dpi) of PBS-treated (open symbols, n = 7), PTX-treated (black symbols, n = 9), or PTB-treated (gray symbols, n = 6) BLT-NSG mice. Mice were sacrificed at 14 (triangles) or 21 (circles) dpi. One mouse with positive viremia at 14 dpi is shown in red, and 2 mice with positive viremia at 21 dpi are shown in orange and yellow. (C) HIV RNA in tissue at 14 (triangles) or 21 (circles) dpi. Tissues corresponding to the 3 mice with positive viremia are shown as in B. Of note, for some of the aLN samples the amount and quality of RNA was insufficient for analysis and gut samples from 3 PBS- and 3 PTX-treated mice were not collected. Dotted line: limit of sensitivity of the assay; gray box: mean of 3 to 5 uninfected animals ± 2 SD. CVT, cervico-vaginal tissue; LNs, lymph nodes; cLNs, cervical LNs; aLNs, axillary LNs; mLNs, mesenteric LNs. Fisher exact tests were used to perform statistical comparisons of the number of viremic and nonviremic tissues in treated versus untreated mice. *P < 0.05,**P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts